{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:27:22Z","timestamp":1794360442945,"version":"4.9.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.jaad.2015.01.014","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T01:30:52Z","timestamp":1426037452000},"page":"879-889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology"],"prefix":"10.1016","volume":"72","author":[{"given":"Alexander L.","family":"Fogel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharleen","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce M.C.","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2015.01.014_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jaad.2007.05.021","article-title":"Sirolimus (rapamycin): from the soil of Easter Island to a bright future","volume":"57","author":"Paghdal","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12154-008-0003-5","article-title":"Rapamycin and mTOR kinase inhibitors","volume":"1","author":"Ballou","year":"2008","journal-title":"J Chem Biol"},{"key":"10.1016\/j.jaad.2015.01.014_bib3","unstructured":"Pfizer. Rapamune package insert. Online2012. Available at: http:\/\/labeling.pfizer.com\/showlabeling.aspx?id=139. Accessed August 1, 2014."},{"key":"10.1016\/j.jaad.2015.01.014_bib4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jdermsci.2009.07.008","article-title":"Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients","volume":"56","author":"Hickerson","year":"2009","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2015.01.014_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1440-0960.2011.00837.x","article-title":"Topical 0.1% rapamycin for angiofibromas in pediatric patients with tuberous sclerosis: a pilot study of four patients","volume":"53","author":"Foster","year":"2012","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/lsm.20890","article-title":"Long-term blood vessel removal with combined laser and topical rapamycin antiangiogenic therapy: implications for effective port wine stain treatment","volume":"42","author":"Jia","year":"2010","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.jaad.2015.01.014_bib7","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2133.2005.06438.x","article-title":"Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial","volume":"152","author":"Ormerod","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/med.20049","article-title":"Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment","volume":"26","author":"Jozwiak","year":"2006","journal-title":"Med Res Rev"},{"key":"10.1016\/j.jaad.2015.01.014_bib9","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: a new generation of mTOR inhibitors","volume":"10","author":"Benjamin","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaad.2015.01.014_bib10","unstructured":"Drugs@FDA: FDA-approved drug products. Online: U.S. Food and Drug Administration; 2014. Available at: http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm. Accessed August 1, 2014."},{"key":"10.1016\/j.jaad.2015.01.014_bib11","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000338893","article-title":"Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor","volume":"224","author":"Peuvrel","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2015.01.014_bib12","doi-asserted-by":"crossref","first-page":"E34","DOI":"10.3816\/CGC.2009.n.019","article-title":"Eosinophilic rash secondary to temsirolimus","volume":"7","author":"Gandhi","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.jaad.2015.01.014_bib13","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","article-title":"Rapamycin causes regression of astrocytomas in tuberous sclerosis complex","volume":"59","author":"Franz","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaad.2015.01.014_bib14","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1586\/era.11.93","article-title":"Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis","volume":"11","author":"Franz","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jaad.2015.01.014_bib15","doi-asserted-by":"crossref","first-page":"e1335","DOI":"10.1542\/peds.2010-2910","article-title":"Regression of a cardiac rhabdomyoma in a patient receiving everolimus","volume":"127","author":"Tiberio","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2015.01.014_bib16","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","article-title":"Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial","volume":"17","author":"Davies","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2015.01.014_bib17","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.arbr.2011.01.007","article-title":"Lymphangioleiomyomatosis treatment with sirolimus","volume":"47","author":"Casanova","year":"2011","journal-title":"Archivos de bronconeumologia"},{"key":"10.1016\/j.jaad.2015.01.014_bib18","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1093\/hmg\/ddt288","article-title":"Birt-Hogg-Dube syndrome is a novel ciliopathy","volume":"22","author":"Luijten","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jaad.2015.01.014_bib19","unstructured":"Steense Mv. Topical rapamycin for fibrofolliculomas. In: U. N. I. o. Health editor. Online2013. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00928798?term=birt+hogg+dube&rank=2. Accessed August 1, 2014."},{"key":"10.1016\/j.jaad.2015.01.014_bib20","doi-asserted-by":"crossref","first-page":"259.e1","DOI":"10.1016\/j.jaad.2010.11.039","article-title":"Familial multiple discoid fibromas: a look-alike of Birt-Hogg-Dube syndrome not linked to the FLCN locus","volume":"66","author":"Starink","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/jmg.2004.018036","article-title":"Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome","volume":"41","author":"Pilarski","year":"2004","journal-title":"J Med Genet"},{"key":"10.1016\/j.jaad.2015.01.014_bib22","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1158\/0008-5472.CAN-08-0922","article-title":"Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin","volume":"68","author":"Squarize","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2015.01.014_bib23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ncponc1112","article-title":"Rapamycin treatment for a child with germline PTEN mutation","volume":"5","author":"Marsh","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.jaad.2015.01.014_bib24","unstructured":"Rajan A. Sirolimus to treat Cowden syndrome and other PTEN hamartomatous tumor syndromes. In: T. U. S. N. I. o. Health editor. ClinicalTrials.gov2009. Available at: http:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT00971789?term=pten+rapamycin&rank=1&sect=X736015#outcome2. Accessed August 1, 2014."},{"key":"10.1016\/j.jaad.2015.01.014_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.abb.2010.12.019","article-title":"Keratin gene mutations in disorders of human skin and its appendages","volume":"508","author":"Chamcheu","year":"2011","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.jaad.2015.01.014_bib26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00403-012-1288-3","article-title":"Visible effects of rapamycin (sirolimus) on human skin explants in\u00a0vitro","volume":"305","author":"Peramo","year":"2013","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2015.01.014_bib27","unstructured":"ClinicalTrials.gov. Online: The United States National Institutes of Health; 2014."},{"key":"10.1016\/j.jaad.2015.01.014_bib28","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin\u00a0inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2015.01.014_bib29","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1167\/iovs.04-0753","article-title":"Inhibitory effect of rapamycin on corneal neovascularization in\u00a0vitro and in\u00a0vivo","volume":"46","author":"Kwon","year":"2005","journal-title":"Invest Ophthalmol Visl Sci"},{"key":"10.1016\/j.jaad.2015.01.014_bib30","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archderm.143.4.504","article-title":"AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in\u00a0vivo","volume":"143","author":"Perry","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/lsm.20599","article-title":"Can the wound healing response of human skin be modulated after laser treatment and the effects of exposure extended? Implications on the combined use of the pulsed dye laser and a topical angiogenesis inhibitor for treatment of port wine stain birthmarks","volume":"40","author":"Phung","year":"2008","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.jaad.2015.01.014_bib32","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1056\/NEJMoa1213507","article-title":"Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ","volume":"368","author":"Shirley","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2015.01.014_bib33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/lrb.2007.1012","article-title":"Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in\u00a0vivo","volume":"5","author":"Shirazi","year":"2007","journal-title":"Lymph Res Biol"},{"key":"10.1016\/j.jaad.2015.01.014_bib34","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/(SICI)1096-9101(1996)19:2<224::AID-LSM15>3.0.CO;2-6","article-title":"Dynamic epidermal cooling in conjunction with laser-induced photothermolysis of port wine stain blood vessels","volume":"19","author":"Nelson","year":"1996","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.jaad.2015.01.014_bib35","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/lsm.22101","article-title":"Topical rapamycin suppresses the angiogenesis pathways induced by pulsed dye laser: molecular mechanisms of inhibition of regeneration and revascularization of photocoagulated cutaneous blood vessels","volume":"44","author":"Tan","year":"2012","journal-title":"Lasers Surg Med"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2015.01.014_bib36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-0560.2010.01520.x","article-title":"Stem cell marker upregulation in normal cutaneous vessels following pulsed-dye laser exposure and its abrogation by concurrent rapamycin administration: implications for treatment of port-wine stain birthmarks","volume":"37","author":"Loewe","year":"2010","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2015.01.014_bib37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1525-1470.2012.01879.x","article-title":"Propranolol use in PHACE syndrome with cervical and intracranial arterial anomalies: collective experience in 32 infants","volume":"30","author":"Metry","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib38","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1111\/pde.12023","article-title":"Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome","volume":"30","author":"Kaylani","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib39","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/pbc.22766","article-title":"Treatment of childhood kaposiform hemangioendothelioma with sirolimus","volume":"55","author":"Blatt","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaad.2015.01.014_bib40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00595-005-3138-9","article-title":"TIE2 gain-of-function mutation in a patient with pancreatic lymphangioma associated with blue rubber-bleb nevus syndrome: report of a case","volume":"36","author":"Nobuhara","year":"2006","journal-title":"Surg today"},{"key":"10.1016\/j.jaad.2015.01.014_bib41","doi-asserted-by":"crossref","first-page":"e1080","DOI":"10.1542\/peds.2010-3611","article-title":"Blue rubber bleb nevus syndrome: successful treatment with sirolimus","volume":"129","author":"Yuksekkaya","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2015.01.014_bib42","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/pbc.23124","article-title":"Sirolimus for the treatment of complicated vascular anomalies in children","volume":"57","author":"Hammill","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaad.2015.01.014_bib43","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/1940-6207.CAPR-12-0272-T","article-title":"Inhibition of mTOR suppresses UVB-induced keratinocyte proliferation and survival","volume":"5","author":"Carr","year":"2012","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.jaad.2015.01.014_bib44","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1158\/1940-6207.CAPR-10-0375","article-title":"Rapamycin is a potent inhibitor of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate","volume":"4","author":"Checkley","year":"2011","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.jaad.2015.01.014_bib45","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1002\/cncr.25320","article-title":"Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium","volume":"116","author":"Hainsworth","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2015.01.014_bib46","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1600-0625.2010.01102.x","article-title":"Cutaneous T-cell lymphoma cells are sensitive to rapamycin","volume":"19","author":"Kremer","year":"2010","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib47","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1016\/j.transproceed.2012.09.025","article-title":"Sirolimus for the treatment of Kaposi sarcoma after renal transplantation: a series of 10 cases","volume":"44","author":"Yaich","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jaad.2015.01.014_bib48","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/01.TP.0000115344.18025.0B","article-title":"Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma","volume":"77","author":"Campistol","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.jaad.2015.01.014_bib49","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa042831","article-title":"Sirolimus for Kaposi's sarcoma in renal-transplant recipients","volume":"352","author":"Stallone","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2015.01.014_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbmt.2010.05.011","article-title":"Consensus Conference on Clinical Practice in Chronic GVHD: second-line treatment of chronic graft-versus-host disease","volume":"17","author":"Wolff","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaad.2015.01.014_bib51","first-page":"495212","article-title":"Site-specific immunosuppression in vascularized composite allotransplantation: prospects and potential","volume":"2013","author":"Schnider","year":"2013","journal-title":"Clini Dev Immunol"},{"key":"10.1016\/j.jaad.2015.01.014_bib52","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/art.24986","article-title":"Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study","volume":"60","author":"Su","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2015.01.014_bib53","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.bbmt.2010.07.025","article-title":"Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors","volume":"17","author":"Jedlickova","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaad.2015.01.014_bib54","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000172830","article-title":"Treatment of refractory oral erosive lichen planus with topical rapamycin: 7 cases","volume":"218","author":"Soria","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2015.01.014_bib55","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1177\/0883073813488664","article-title":"A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex","volume":"28","author":"Wheless","year":"2013","journal-title":"J Child Neurol"},{"key":"10.1016\/j.jaad.2015.01.014_bib56","unstructured":"Oxford Centre for Evidence-based Medicine - Levels of Evidence. Online2009. Available at: http:\/\/www.cebm.net\/?o=1025. Accessed August 1, 2014."},{"key":"10.1016\/j.jaad.2015.01.014_bib57","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bjd.12315","article-title":"Familial multiple discoid fibromas: unique histological features and therapeutic response to topical rapamycin","volume":"169","author":"Wee","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib58","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1016\/j.jaad.2012.04.032","article-title":"Topical sirolimus for oral pemphigus vulgaris: 3 unresponsive cases","volume":"67","author":"Poot","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib59","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archdermatol.2010.125","article-title":"Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis","volume":"146","author":"Haemel","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib60","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1001\/archdermatol.2011.254","article-title":"Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol","volume":"147","author":"DeKlotz","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib61","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1365-2133.2011.10476.x","article-title":"Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis","volume":"165","author":"Mutizwa","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib62","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1365-2133.2011.10471.x","article-title":"A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity","volume":"165","author":"Wataya-Kaneda","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib63","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/09546634.2010.489598","article-title":"Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin","volume":"23","author":"Kaufman McNamara","year":"2012","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2015.01.014_bib64","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11634580-000000000-00000","article-title":"Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin","volume":"12","author":"Koenig","year":"2012","journal-title":"Drugs R D"},{"key":"10.1016\/j.jaad.2015.01.014_bib65","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1468-3083.2011.04212.x","article-title":"Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis\u2013associated facial angiofibroma","volume":"26","author":"Salido","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2015.01.014_bib66","first-page":"15","article-title":"Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response","volume":"18","author":"Truchuelo","year":"2012","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2015.01.014_bib67","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/archderm.148.1.138","article-title":"A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex","volume":"148","author":"Wataya-Kaneda","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib68","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/bjd.12567","article-title":"First left-right comparative study of topical rapamycin vs vehicle for facial angiofibromas in patients with tuberous sclerosis complex","volume":"169","author":"Tanaka","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/ajd.12125","article-title":"Topical rapamycin for angiofibromas in pediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions","volume":"55","author":"Tu","year":"2014","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib70","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation","volume":"367","author":"Euvrard","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2015.01.014_bib71","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1365-2133.2001.04376.x","article-title":"Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial","volume":"145","author":"Reitamo","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib72","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/onc.2009.14","article-title":"The role of the Birt-Hogg-Dube protein in mTOR activation and renal tumorigenesis","volume":"28","author":"Hartman","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.jaad.2015.01.014_bib73","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1016\/j.jaad.2010.08.023","article-title":"The cutaneous effects of post-transplant immunosuppression with cyclosporine in Muir-Torre syndrome","volume":"64","author":"Griffard","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib74","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaad.2009.05.039","article-title":"Pediatric teledermatology: observations based on 429 consults","volume":"62","author":"Chen","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib75","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1200\/JCO.2012.41.7287","article-title":"Efficacy of rapamycin for refractory hemangioendotheliomas in Maffucci's syndrome","volume":"30","author":"Riou","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2015.01.014_bib76","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1365-2133.2005.06745.x","article-title":"Cilomilast, tacrolimus and rapamycin modulate dendritic cell function in the elicitation phase of allergic contact dermatitis","volume":"153","author":"Baumer","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib77","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jaad.2011.01.029","article-title":"Sirolimus for acute pemphigus vulgaris: a case report and discussion of dualistic action providing for both immunosuppression and keratinocyte protection","volume":"65","author":"Grando","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.01.014_bib78","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/jid.2012.483","article-title":"Potent dual inhibitors\u00a0of TORC1 and TORC2 complexes (KU-0063794 and KU-0068650) demonstrate in\u00a0vitro and ex\u00a0vivo anti-keloid scar activity","volume":"133","author":"Syed","year":"2013","journal-title":"J Invest Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215000547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215000547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:34:58Z","timestamp":1759271698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962215000547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0190962215000547"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2015.01.014","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2015.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}